Journal article
Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: Impaired viral kinetics and therapeutic response
S Naggie, A Osinusi, A Katsounas, R Lempicki, E Herrmann, AJ Thompson, PJ Clark, K Patel, AJ Muir, JG McHutchison, JF Schlaak, M Trippler, B Shivakumar, H Masur, MA Polis, S Kottilil
Hepatology | Published : 2012
DOI: 10.1002/hep.25647
Abstract
Recent studies have shown that a single-nucleotide polymorphism upstream of the interleukin-28B (IL28B) gene plays a major role in predicting therapeutic response in hepatitis C virus (HCV)-infected patients treated with pegylated interferon (PEG-IFN)/ribavirin. We sought to investigate the mechanism of the IL28B polymorphism, specifically as it relates to early HCV viral kinetics, IFN pharmacokinetics, IFN pharmacodynamics, and gene expression profiles. Two prospective cohorts (human immunodeficiency virus [HIV]/HCV-coinfected and HCV-monoinfected) completing treatment with IFN/ribavirin were enrolled. Patients were genotyped at the polymorphic site rs12979860. In the HIV/HCV cohort, freque..
View full abstractGrants
Awarded by National Institute of Allergy and Infectious Diseases
Funding Acknowledgements
Supported in whole or in part by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Cancer Institute, National Institutes of Health, under contract no. HSN261200800001E.